Pear Therapeutics to Participate in the 2020 BTIG Virtual Biotechnology Conference and the Canaccord Genuity 40th Annual Growth Conference
Boston, August 4, 2020 – Pear Therapeutics, Inc. today announced management’s participation in the following investors conferences in August:
- August 10-11: 2020 BTIG Virtual Biotechnology Conference. Corey McCann, M.D., Ph.D., President and CEO, will participate in an analyst-led fireside chat at this virtual conference on Tuesday, August 11, 2020 at 1:30 p.m. ET.
- August 11-13: Canaccord Genuity 40th Annual Growth Conference. Corey McCann will participate in the HCIT: Digital Therapeutics Panel at this virtual conference on Thursday, August 13, 2020 at 9:00 a.m. ET.
Pear Therapeutics is a privately held, prescription digital therapeutics company developing clinically validated, FDA-authorized software applications to treat serious disease.
About Pear Therapeutics
Pear Therapeutics is the leader in prescription digital therapeutics, or PDTs. Pear aims to redefine medicine by discovering, developing, and delivering clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from FDA. Pear’s lead product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst™, for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program. For more information, visit Pear at www.peartherapeutics.com.
Media and Investors:
Meara Murphy, Director, Corporate Communications